Printer Friendly

CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT

CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT
 PRINCETON, N.J., Aug. 12 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) and Cytorad Incorporated (NASDAQ: CYTDZ), reported the initiation of Phase I human clinical trials for OncoRad(R) prostate, the company's second cancer therapeutic product in clinical development.
 The Phase I studies are designed primarily to determine the maximum tolerated dose, and they will initially take place at two leading U.S. cancer centers.
 OncoRad prostate is a monoclonal antibody (MAb)-based cancer therapeutic agent which is designed to target the cytotoxic radioisotope Yttrium-90 to cancer cells in the body of patients with prostate cancer. The product development objective is to kill the cancer cells while sparing normal tissue, thereby reducing side effects associated with standard chemotherapy and radiation therapy. The American Cancer Society states that prostate cancer is the second most common cancer in men; approximately one of every 11 men will develop this disease in their lifetime. In 1992, an estimated 132,000 new cases of prostate cancer will occur in the United States and nearly 34,000 will die from the disease.
 In commenting on this new product, Cytogen President Thomas J. McKearn M.D., Ph.D., said, "We begin Phase I trials with a sense of confidence, because the new OncoRad product utilizes the same delivery vehicle as our OncoScint(R) prostate cancer imaging agent and the same radioisotope as our OncoRad ovarian cancer therapy agent. Both of these products have experienced success in the clinic, thus far." He continues, "This initiation of Phase I trials further solidifies Cytogen's position as a leader, with one of the most extensive pipelines for cancer products in the world."
 Cytogen is a biopharmaceutical company engaged in the development of products utilizing monoclonal antibodies for the targeted delivery of diagnostic and therapeutic substances. Cytogen uses its patented and proprietary antibody "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 Cytorad is a newly formed company which, through Cytogen, will engage in the research and development of proprietary antibody-based delivery systems for diagnosis and treatment of prostate and bladder cancers.
 /delval/
 -0- 8/12/92
 /CONTACT: Martin D. Cleary, group vice president of Cytogen, 609-987-8221/
 (CYTO CYTD) CO: Cytogen Corporation; Cytorad Incorporated ST: New Jersey IN: MTC SU:


MP -- PH008 -- 9290 08/12/92 09:49 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 12, 1992
Words:389
Previous Article:BLESSINGS CORPORATION REPORTS STRONG SALES AND EARNINGS FOR THE SECOND QUARTER ENDING JULY 11, 1992
Next Article:CREST INDUSTRIES ANNOUNCES SIGNING OF LETTER OF INTENT RELATING TO PROPOSED BUSINESS COMBINATION
Topics:


Related Articles
CYTOGEN AND CYTORAD ANNOUNCE UNIT OFFERING
CYTOGEN ANNOUNCES 1992 ANNUAL MEETING HIGHLIGHTS
CYTOGEN CORPORATION ANNOUNCES THIRD QUARTER RESULTS
CYTOGEN CORPORATION ANNOUNCES FOURTH QUARTER RESULTS
CYTOGEN ACQUIRES RIGHTS TO UNILEVER CANCER PROGRAM
CYTOGEN AND CYTORAD ANNOUNCE EXPANDED AGREEMENT
CYTOGEN ANNOUNCES RESULTS COMPARING TWO CANCER IMAGING AGENTS
CYTOGEN WELCOMES MICHAEL R. KURMAN AS DIRECTOR OF CANCER THERAPEUTICS, CLINICAL INVESTIGATIONS
CELLCOR TO MANUFACTURE NEOPROBE'S CELL THERAPY PRODUCT
Reportlinker Adds World Cancer Therapies Market Report.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters